CONCLUSION
In conclusion, co-administered evogliptin and glimepiride had no PK
interactions, but exerted an additive glucose lowering effect compared
to evogliptin or glimepiride monotherapy. Therefore, the combination
therapy with evogliptin and glimepiride may be an alternative option for
T2DM patients with inadequate glycemic control using either a DPP-4
inhibitor or sulfonylurea.